Clarity Pharmaceuticals Ltd - Asset Resilience Ratio

Latest as of December 2025: 73.99%

Clarity Pharmaceuticals Ltd (CU6) has an Asset Resilience Ratio of 73.99% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$189.17 Million

≈ $133.85 Million USD Cash + Short-term Investments

Total Assets

AU$255.67 Million

≈ $180.90 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Clarity Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Check CU6 strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Clarity Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Clarity Pharmaceuticals Ltd.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$33.37 Million	13.05%
Short-term Investments	AU$155.80 Million	60.94%
Total Liquid Assets	AU$189.17 Million	73.99%

Asset Resilience Insights

Very High Liquidity: Clarity Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 73.99% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Clarity Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Clarity Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	39.07%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%

Annual Asset Resilience Ratio for Clarity Pharmaceuticals Ltd (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Clarity Pharmaceuticals Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-06-30	65.08%	AU$65.84 Million ≈ $46.59 Million	AU$101.17 Million ≈ $71.59 Million	-2.05pp
2024-06-30	67.13%	AU$103.80 Million ≈ $73.45 Million	AU$154.63 Million ≈ $109.41 Million	-9.65pp
2023-06-30	76.78%	AU$59.04 Million ≈ $41.77 Million	AU$76.90 Million ≈ $54.41 Million	+14.67pp
2022-06-30	62.11%	AU$62.00 Million ≈ $43.87 Million	AU$99.82 Million ≈ $70.63 Million	+15.68pp
2021-06-30	46.43%	AU$10.50 Million ≈ $7.43 Million	AU$22.61 Million ≈ $16.00 Million	+35.46pp
2020-06-30	10.97%	AU$1.00 Million ≈ $707.56K	AU$9.12 Million ≈ $6.45 Million	-32.67pp
2019-06-30	43.65%	AU$4.52 Million ≈ $3.20 Million	AU$10.36 Million ≈ $7.33 Million	--

pp = percentage points

About Clarity Pharmaceuticals Ltd

AU:CU6 Australia Biotechnology

Market Cap

$711.17 Million

AU$1.01 Billion AUD

Market Cap Rank

#10429 Global

#276 in Australia

Share Price

AU$2.70

Change (1 day)

+7.14%

52-Week Range

AU$1.82 - AU$5.70

All Time High

AU$8.79